Celltrion Founder Plans To Sell Stake To Keep Drug Firm In S. Korea Hands
This article was originally published in PharmAsia News
Executive Summary
Celltrion Founder Seo Jung-jin plans to sell his entire 40% stake in the South Korea drug manufacturer – a potential $1.48 billion selloff – and has drawn interest from 10 strategic and financial investors.